Gordon Mazibrada

106 (NOT) comparing apples with apples; MS hospital episode statistics dashboard highlights variation in trusts’ reporting

David Rog, Jeremy Hobart, Jake Clements, Jamie McGregor et autres

Introduction GIRFT utilises comparator data to assess variation in practice, including HES data. Context and accuracy underpin meaningful data analysis. Dashboards enable similar components of service delivery to be compared and benchmarked. Methods DR, JH and JM, worked with JC, to develop …

gb (code pays fourni par la source)

125 Towards an optimal multiple sclerosis patient case-load for a full-time MSologist

Gavin Giovannoni, Jeremy Hobart, Gordon Mazibrada, Karen Bateman et autres

Introduction Strategy, evidence and anticipation should underpin workforce-planning. Aim To estimate a sustainable patient-caseload (PCL) for a full-time equivalent MS specialist neurologist (FTE-MSologist). Methods Hypothetically, an FTE-MSologist refers to 10-MSology-related programmed activities per week. We considered three service models (core, aspirational, alternative/DGH) …

gb (code pays fourni par la source)

Adult-Onset Still Disease as a Novel Autoimmune Complication of Alemtuzumab Therapy: A Case Report and Review of Alemtuzumab-Associated Autoimmune Disease.

Nehal Narayan, Gordon Mazibrada, Nicole Amft

gb (code pays fourni par la source)

The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review

Saiju Jacob, Gordon Mazibrada, Sarosh R. Irani, Anu Jacob et autres

Autoimmune neurological disorders are commonly treated with immunosuppressive therapy. In patients with refractory conditions, standard immunosuppression is often insufficient for complete recovery or to prevent relapses. These patients rely on other treatments to manage their disease. While treatment of refractory cases differs …

gb, be (code pays fourni par la source)

Adult-Onset Still Disease as a Novel Autoimmune Complication of Alemtuzumab Therapy

Nehal Narayan, Gordon Mazibrada, Nicole Amft

Department of Rheumatology Queen Elizabeth Hospital Birmingham Birmingham United Kingdom [email protected]. Department of Neurology Queen Elizabeth Hospital Birmingham Birmingham United Kingdom Department of Rheumatology Queen Elizabeth Hospital Birmingham Birmingham United Kingdom The authors declare no conflict of interest. No funding was …

gb, es (code pays fourni par la source)

P23 Adult onset Still’s disease as a novel autoimmune complication of alemtuzumab therapy: a case report and review of alemtuzumab associated autoimmune disease

Nehal Narayan, Gordon Mazibrada, Nicole Amft

Abstract Background Alemtuzumab is a monoclonal antibody targeted to CD52, an antigen of uncertain function on T and B lymphocytes. Alemtuzumab is an established treatment for active relapsing and remitting multiple sclerosis (MS). However, autoimmune disease (AID) is being increasingly recognised as …

gb (code pays fourni par la source)

Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging

I‐Jun Chou, Radu Tănăsescu, Olivier Mougin, Penny Gowland et autres

Whether the integrity of normal-appearing white matter (NAWM) is preserved in neuromyelitis optica spectrum disorders (NMOSD) is open to debate. To examine whether the tissue integrity of NAWM in NMOSD is compromised compared to that in healthy controls and patients with multiple …

gb, tw, ro (code pays fourni par la source)

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK

Gordon Mazibrada, Charlotte Sharples, Ines Perfect

BACKGROUND: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. OBJECTIVE: To evaluate retrospectively the effectiveness and safety of fingolimod in patients …

gb (code pays fourni par la source)

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

María Trojano, Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl et autres

BACKGROUND: Though the Expanded Disability Status Scale (EDSS) is commonly used to assess disability level in relapsing-remitting multiple sclerosis (RRMS), the criteria defining disability progression are used for patients with a wide range of baseline levels of disability in relatively short-term trials. …

it, au, ch, de, us (code pays fourni par la source)

GILENYA PATIENT CHARACTERISTICS IN THE UK

Gordon Mazibrada, Paula Pamies Garcia-Ganuza

Background Fingolimod (Gilenya) is a sphingosine 1-phosphate receptor modulator. Fingolimod was first granted a European license in multiple sclerosis in 2011 and first approved for use in the UK by the National Institute for Health and Care Excellence (NICE) in 2012 for …

gb, fr (code pays fourni par la source)

MS FINE STUDY: GILENYA REAL WORLD EXPERIENCE IN THE UK

Gordon Mazibrada, Paula Pamies Garcia-Ganuza

Background Fingolimod (Gilenya) is a sphingosine 1-phosphate receptor modulator. Fingolimod was first granted a European license in multiple sclerosis in 2011 and first approved for use in the UK by the National Institute for Health and Care Excellence (NICE) in 2012 for …

gb, fr (code pays fourni par la source)

Extreme delta brushes and BIRDs in the EEG of anti-NMDA-receptor encephalitis

Ahmed M. Abbas, Ashish Garg, Rajdeep Jain, Gordon Mazibrada et autres

A 23-year-old Caucasian woman presented acutely to the emergency department with mild confusion and recurring stereotyped seizures that comprised a tingling sensation in her right arm and leg, followed by a generalised tonic–clonic seizure. She had been diagnosed with anti- N -methyl …

gb (code pays fourni par la source)